Womenra is a prescription medication specifically developed to address acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It contains flibanserin, a multifunctional serotonin agonist and antagonist that works centrally to rebalance neurotransmitters associated with sexual interest. Unlike hormonal therapies, Womenra targets the brain’s chemistry to help revive spontaneous sexual thoughts and receptivity, offering a non-hormonal option for women distressed by their low libido. Clinical studies support its efficacy in improving satisfying sexual events and desire scores, making it a scientifically validated choice for appropriate candidates under medical supervision.

Features

• Active ingredient: Flibanserin 100 mg
• Form: Oral tablet
• Mechanism: Central serotonin 5-HT1A agonist and 5-HT2A antagonist
• Non-hormonal mode of action
• FDA-approved for premenopausal women with HSDD
• Requires prescription and healthcare provider consultation

Benefits

• Increases the number of satisfying sexual events per month
• Enhances spontaneous sexual desire and reduced distress about low libido
• Provides a non-hormonal treatment alternative for sexual dysfunction
• Improves overall sexual satisfaction and intimacy
• Supported by randomized controlled clinical trials
• Helps restore a sense of normalcy in sexual relationships

Common use

Womenra is indicated for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women who have not previously experienced issues with low sexual desire. It is intended for those who report a noticeable decrease in sexual interest that causes personal distress and is not attributable to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or substance. Diagnosis should be confirmed by a healthcare provider specializing in sexual health or women’s wellness.

Dosage and direction

The recommended dosage of Womenra is one 100 mg tablet taken orally once daily, at bedtime. Administration at bedtime is advised to mitigate the risk of hypotension, syncope, and central nervous system depression such as somnolence. It may be taken with or without food, though consistency in timing is recommended. Patients should not consume alcohol or use other CNS depressants on the same day as dosing. Treatment efficacy should be evaluated after 8 weeks of continuous use. Do not exceed the prescribed dose.

Precautions

• Avoid concomitant use of alcohol due to increased risk of severe hypotension and syncope.
• Use with caution in patients with hepatic impairment; not recommended in severe hepatic impairment.
• May cause dizziness, sleepiness, or fatigue; avoid activities requiring full alertness, such as driving, until the effect is known.
• Not recommended for use in postmenopausal women or men.
• Blood pressure should be monitored, especially when initiating treatment.
• Inform your healthcare provider of all medications, supplements, and medical history before use.

Contraindications

Womenra is contraindicated in:

• Patients with hepatic impairment.
• Concomitant use with strong or moderate CYP3A4 inhibitors (e.g., ketoconazole, fluconazole, erythromycin).
• Use with alcohol or other CNS depressants.
• Hypersensitivity to flibanserin or any component of the formulation.
• Postmenopausal women and men.
• Patients with a history of hypotension or syncope episodes.

Possible side effect

Common side effects may include:

• Dizziness
• Somnolence (sleepiness)
• Nausea
• Fatigue
• Insomnia
• Dry mouth

Rare but serious side effects can include:

• Hypotension
• Syncope (fainting)
• Central nervous system depression

Patients should seek medical attention if they experience severe dizziness, loss of consciousness, or any unusual symptoms.

Drug interaction

Womenra has several important drug interactions:

• Strong or moderate CYP3A4 inhibitors significantly increase flibanserin exposure and are contraindicated.
• Concomitant use with alcohol increases risk of hypotension and syncope; avoid alcohol.
• CNS depressants (e.g., benzodiazepines, opioids, sleep aids) may enhance sedative effects.
• Use with antihypertensive medications may increase risk of hypotension.
• Flibanserin is a weak CYP3A4 inducer and CYP2C9/2C19 inhibitor; monitor medications metabolized by these enzymes.

Consult a healthcare provider for a comprehensive medication review before starting Womenra.

Missed dose

If a dose is missed, skip it and take the next dose at the regular time the following bedtime. Do not double the dose to make up for a missed one. Taking extra tablets can increase the risk of adverse effects such as hypotension or severe drowsiness.

Overdose

Symptoms of overdose may include severe hypotension, syncope, and CNS depression such as profound drowsiness or coma. In case of suspected overdose, seek immediate medical attention or contact a poison control center. Supportive care, including monitoring of vital signs and symptomatic treatment, is recommended. There is no specific antidote for flibanserin overdose.

Storage

Store Womenra tablets at room temperature (20°–25°C or 68°–77°F), in a dry place, away from direct light and moisture. Keep the bottle tightly closed and out of reach of children and pets. Do not use after the expiration date printed on the packaging.

Disclaimer

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Do not disregard professional medical advice or delay in seeking it because of something you have read here.

Reviews

“After six months on Womenra, I feel like myself again. The initial sleepiness faded, and my interest in intimacy returned without feeling forced. It’s been a relief.” – Maria, 38

“As a gynecologist, I’ve seen Womenra help appropriately selected patients regain confidence and reduce distress around their sexuality. It’s not for everyone, but for the right candidate, it can be transformative under careful supervision.” – Dr. Elena Rostova, MD

“The no-alcohol rule was challenging socially, but the improvement in my relationship and self-esteem made it worthwhile. I wish I’d known about this option years ago.” – Chloe, 42